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6-N-[(di-n-butylamino)methylene]-3'-{[N-(9-fluorenyl)methoxycarbonyl-S-(3-nitro-2-pyridinesulfenyl)-L-ß,ß-dimethylcysteinyl]amino}-3'-deoxy-5'-O-(4,4'-dimethoxytrityl)-ß-D-adenosine (rA-Pen·1)
Fmoc-Pen(NPys)-OH (66 mg, 0.26 mmol) was activated with 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU, 99 mg, 0.26 mmol) and N,N-diisopropylethylamine (DIPEA, 44 µL) in 2.7 mL dry DMF under argon atmosphere for 8 minutes. Then 3'-Amino-6-N-[(di-n- Compound rA-Pen·1 (79 mg, 0.065 mmol) was dissolved in 900 µL dry DMF and 900 µL dry pyridine. 
Synthesis of cysteine functionalized dA 3'NH solid support dA-GlyCys

N-Allyloxycarbonyl-L-glycine
L-Glycine (1 g, 13.3 mmol) and 5.5 eq Na 2 CO 3 (7.8 g, 73.3 mmol) were suspended in 60 mL tetrahydrofuran (THF)/H 2 O (1/2) and cooled to 0°C. Then 1.2 eq diallyl pyro carbonate (2.6 mL, 16.0 mmol) were added and the reaction mixture stirred over night at room temperature. After washing the reaction mixture three times with diethyl ether, the aqueous phase was acidified with concentrated
HCl to pH 1 and extracted three times with CH 2 Cl 2 . The organic phase was dried over Na 2 SO 4 . The product was obtained as colorless oil.
1
H NMR (300 MHz, DMSO):
.90 mmol) and 1.1 eq Nallyloxycarbonyl-L-glycine pentafluorophenylester (1.4 g, 4.30 mmol) were suspended in a mixture of dry DMF (6 mL) and dry pyridine (6 mL). The reaction was stirred for 1.5 hours at room temperature under argon atmosphere. Then 1.6 eq tert.-butyl(chloro)dimethylsilane (941 mg, 6.24 mmol) were added and the reaction mixture was stirred for 16 hours at room temperature under argon atmosphere.
The reaction was quenched with 7 mL MeOH and stirred for another 20 minutes. After evaporation of the solvents, the crude product was taken up in CH 2 Cl 2 and washed with 5% citric acid, saturated Compound dA-Gly·1 (701 mg, 1.40 mmol) and 7.5 eq 3-(2,6-dioxotetrahydro-2H-pyran-3-yl)propanoic acid 6 (1.96 g, 10.5 mmol) were dissolved in 8 mL dry pyridine and stirred at 90°C under argon atmosphere for 6 hours. After evaporation of the solvent, the residue was taken up in CH 2 Cl 2 and washed three times with 5% citric acid. 
Solid phase synthesis, deprotection, and purification of 3'-aminoacyl-oligonucleotides
RNA-Cys(StBu) conjugates 22 nt rA-3'-NH-Cys(StBu), 22 nt dA-3'-NH-Cys(StBu) and 18 nt rA-3'-NHCys(StBu) were prepared as described in reference 4.
Deprotection of the 5'-O-tert.-butyldimethylsilyl (tbdms) group of solid supports dA-Cys·4 and dA-GlyCys prior to DNA synthesis
The solid support (~30 mg) was treated with a solution of 1 M tetrabutylammonium fluoride trihydrate (TBAF·3 H 2 O) and 0.5 M acidic acid in THF (1 mL) for 30 minutes. Then, the beads were collected on a small Büchner funnel, washed with DMF (4 × 2 mL), MeOH (4 × 2 mL) and CH 2 Cl 2 (4 × 2 mL), and dried under vacuum. After RNA synthesis, the solid support was rinsed with 20 mL of 20% piperidine in acetonitrile to remove Fmoc and cyanoethyl groups followed by washing with 20 mL acetonitrile.
Oligonucleotide solid phase synthesis on 3'-aminoacyl-functionalized solid supports
Deprotection of the N-allyloxycarbonyl (alloc) group after oligonucleotide synthesis on
solid supports rA-Cys·3, dA-Cys·4, and dA-GlyCys
The solid support (~30 mg) was suspended in 0.5 mL dry CH 2 Cl 2 and dimethylamine borane ((H 3 C) 2 NH·BH 3 , 7.5 mg, 0.13 mmol) was added. After 10 minutes, tetrakis(triphenylphosphine)palladium ((Ph 3 P) 4 Pd, 25 mg, 0.02 mmol) was added. The reaction mixture was agitated for 2 hours at room temperature under argon atmosphere. Then, the beads were collected on a small
Büchner funnel, washed with 0.5 % sodium diethyldithiocarbamate hydrate in DMF (4 × 2 mL) to remove excess palladium, DMF (4 × 2 mL), MeOH (4 × 2 mL), and CH 2 Cl 2 (4 × 2 mL) and dried under vacuum. 
Deprotection and cleavage of RNA-Pen(NPys) conjugates
Deprotection and cleavage of DNA-Cys(StBu) conjugates
After DNA synthesis, the solid support was rinsed with 20 mL of 20% piperidine in acetonitrile followed by 20 mL acetonitrile to remove cyanoethyl groups. 3'-Cysteinyl-DNA was deprotected with NH 3 in H 2 O (32%, 0.6 mL) and EtOH (0.2 mL) for 16 hours at 55°C. After filtration and evaporation to dryness, the crude 3'-cysteinyl-DNA was dissolved in 1 mL of nanopure H 2 O.
Purification of 3'-aminoacyl-oligonucleotides
Analysis of 18 nt and 22 nt crude 3'-aminoacyl-oligonucleotides after deprotection was performed by anion-exchange chromatography on a Dionex DNAPac ® PA-100 column (4 × 250 mm). Flow rate: 
Mass spectrometry of 3'-aminoacyl-oligonucleotides
The purified 3'-aminoacyl-oligonucleotides were characterized by mass spectrometry on a Finnigan 
Preparation of amino-modified peptide thioester MRFF-ABT
Solid phase peptide synthesis
The peptide was synthesized manually in a 2 mL syringe with a filter membrane following standard Peptide thioesters MFFG-ABT, MLLT-ABT, MRVL-ABT, and MRVW-ABT were synthesized as described in reference 4. Leu-ABT was prepared as described in reference 9. The crude protected peptide acid was analyzed by RP-HPLC and ESI-MS, and used without further purification.
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Synthesis of peptide thioester MRFF-ABT
The ABT group was synthesized in five steps according to the literature. 9 The ABT group (1.4 eq) and the crude protected peptide acid were dissolved with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC·HCl, 4.2 eq) and 4-(dimethylamino)pyridine (DMAP, 4.2 eq) in dry CH 2 Cl 2 under argon atmosphere and stirred for 2 hours at room temperature. 10 After evaporation of the solvents, the residue was taken up in ethylacetate, washed three times with 1 M HCl, three times with 10% 
Analysis and purification of peptides
Analysis of crude products was performed by reversed phase (RP) chromatography on a GE Healthcare 3 mL Resource TM RPC column (6.4 × 100 mm). Flow rate: 2 mL/min; eluant A: 0.1% trifluoroacetic acid (TFA) in H 2 O; eluant B: 0.08% TFA in acetonitrile; 25°C; gradi ent: 5-90% B in A within 20 column volumes; UV-detection at 210 nm. The crude product was purified on the same column using an optimized gradient. Fractions containing peptide were collected and lyophilized.
Mass spectrometry of peptides
Peptides were characterized by electrospray ionization (ESI) mass spectrometry on a Combined fractions of the desulfurized 3'-peptidyl-oligonucleotides were lyophilized.
Mass Spectrometry of 3'-peptidyl-oligonucleotides
The purified 3'-peptidyl-oligonucleotides were characterized by mass spectrometry on a 
